This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded,
placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in
subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung
disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will
include about 314 patients at approximately 120 clinical trial centers. The treatment phase
of the study will last approximately 16 weeks. Patients who complete all required assessments
will also be eligible to enter an open-label, extension study (RIN-PH-202).